BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, Brantly M, Muzyczka N, Byrne BJ, Atkinson M. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA. 1998;95:14384-14388. [PMID: 9826709 DOI: 10.1073/pnas.95.24.14384] [Cited by in Crossref: 230] [Cited by in F6Publishing: 197] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999;73:3994-4003. [PMID: 10196295 DOI: 10.1128/JVI.73.5.3994-4003.1999] [Cited by in Crossref: 401] [Cited by in F6Publishing: 163] [Article Influence: 18.2] [Reference Citation Analysis]
2 Ling C, Zhong L, Srivastava A. Adeno-associated Viral Vectors in Gene Therapy. In: John Wiley & Sons Ltd, editor. eLS. Chichester: John Wiley & Sons, Ltd; 2001. pp. 1-8. [DOI: 10.1002/9780470015902.a0005738.pub3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Modrykamien A, Stoller JK. Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options? Expert Opin Pharmacother 2009;10:2653-61. [PMID: 19827990 DOI: 10.1517/14656560903300111] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Velazquez VM, Bowen DG, Walker CM. Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy. Blood 2009;113:538-45. [PMID: 18566327 DOI: 10.1182/blood-2008-01-131375] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
5 Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009;119:2388-98. [PMID: 19587448 DOI: 10.1172/JCI37607] [Cited by in Crossref: 163] [Cited by in F6Publishing: 124] [Article Influence: 13.6] [Reference Citation Analysis]
6 Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 2005;5:299-310. [PMID: 15975007 DOI: 10.2174/1566523054064968] [Cited by in Crossref: 123] [Cited by in F6Publishing: 108] [Article Influence: 7.7] [Reference Citation Analysis]
7 Keeler AM, Flotte TR. Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome. Hum Gene Ther 2012;23:548-56. [PMID: 22642257 DOI: 10.1089/hum.2012.087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
8 Chiuchiolo MJ, Kaminsky SM, Sondhi D, Mancenido D, Hollmann C, Crystal RG. Phase I/II Study of Intrapleural Administration of a Serotype rh.10 Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human α1-Antitrypsin cDNA to Individuals with α1-Antitrypsin Deficiency. Human Gene Therapy Clinical Development 2014;25:112-33. [DOI: 10.1089/humc.2014.2513] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
9 Grimstein C, Choi YK, Wasserfall CH, Satoh M, Atkinson MA, Brantly ML, Campbell-Thompson M, Song S. Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J Transl Med 2011;9:21. [PMID: 21345239 DOI: 10.1186/1479-5876-9-21] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
10 Boisgerault F, Mingozzi F. The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer. Curr Gene Ther 2015;15:381-94. [PMID: 26122097 DOI: 10.2174/1566523215666150630121750] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
11 Berns KI. The Unusual Properties of the AAV Inverted Terminal Repeat. Hum Gene Ther 2020;31:518-23. [PMID: 32079423 DOI: 10.1089/hum.2020.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
12 Breous E, Somanathan S, Wilson JM. Identification of the immunodominant cytotoxic T-cell epitope of human alpha-1 antitrypsin. Gene Ther 2009;16:1380-2. [PMID: 19693099 DOI: 10.1038/gt.2009.100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
13 Allen JM, Halbert CL, Miller A. Improved Adeno-Associated Virus Vector Production with Transfection of a Single Helper Adenovirus Gene, E4orf6. Molecular Therapy 2000;1:88-95. [DOI: 10.1006/mthe.1999.0010] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 2.3] [Reference Citation Analysis]
14 Li J, Wang D, Qian S, Chen Z, Zhu T, Xiao X. Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther 2003;10:1807-13. [PMID: 12960970 DOI: 10.1038/sj.gt.3302078] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
15 Flotte TR. Gene therapy: the first two decades and the current state-of-the-art. J Cell Physiol 2007;213:301-5. [PMID: 17577203 DOI: 10.1002/jcp.21173] [Cited by in Crossref: 85] [Cited by in F6Publishing: 64] [Article Influence: 6.5] [Reference Citation Analysis]
16 Cramer ML, Shao G, Rodino-Klapac LR, Chicoine LG, Martin PT. Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone. Hum Gene Ther 2017;28:493-509. [PMID: 28345428 DOI: 10.1089/hum.2016.113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
17 Petrache I, Fijalkowska I, Zhen L, Medler TR, Brown E, Cruz P, Choe KH, Taraseviciene-Stewart L, Scerbavicius R, Shapiro L, Zhang B, Song S, Hicklin D, Voelkel NF, Flotte T, Tuder RM. A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006;173:1222-8. [PMID: 16514110 DOI: 10.1164/rccm.200512-1842OC] [Cited by in Crossref: 141] [Cited by in F6Publishing: 71] [Article Influence: 9.4] [Reference Citation Analysis]
18 Shi W, Hemminki A, Bartlett JS. Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. Gynecol Oncol 2006;103:1054-62. [PMID: 16870238 DOI: 10.1016/j.ygyno.2006.06.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
19 Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008;15:858-63. [PMID: 18418415 DOI: 10.1038/gt.2008.68] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 17.4] [Reference Citation Analysis]
20 Duan YY, Wu J, Zhu JL, Liu SL, Ozaki I, Strayer DS, Zern MA. Gene therapy for human alpha1-antitrypsin deficiency in an animal model using SV40-derived vectors. Gastroenterology. 2004;127:1222-1232. [PMID: 15480999 DOI: 10.1053/j.gastro.2004.07.058] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
21 Liu S, Liu F, Schneider AE, St Amand T, Epstein JA, Gutstein DE. Distinct cardiac malformations caused by absence of connexin 43 in the neural crest and in the non-crest neural tube. Development 2006;133:2063-73. [PMID: 16624854 DOI: 10.1242/dev.02374] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
22 Ponnazhagan S, Mahendra G, Curiel DT, Shaw DR. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy. J Virol 2001;75:9493-501. [PMID: 11533211 DOI: 10.1128/JVI.75.19.9493-9501.2001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
23 Mcnulty MJ, Silberstein DZ, Kuhn BT, Padgett HS, Nandi S, Mcdonald KA, Cross CE. Alpha-1 antitrypsin deficiency and recombinant protein sources with focus on plant sources: Updates, challenges and perspectives. Free Radical Biology and Medicine 2021;163:10-30. [DOI: 10.1016/j.freeradbiomed.2020.11.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Mueller C, Flotte TR. Gene-Based Therapy for Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease 2013;10:44-9. [DOI: 10.3109/15412555.2013.764978] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
25 Arruda VR, Stedman HH, Haurigot V, Buchlis G, Baila S, Favaro P, Chen Y, Franck HG, Zhou S, Wright JF, Couto LB, Jiang H, Pierce GF, Bellinger DA, Mingozzi F, Nichols TC, High KA. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 2010;115:4678-88. [PMID: 20335222 DOI: 10.1182/blood-2009-12-261156] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
26 Russell DW, Kay MA. Adeno-Associated Virus Vectors and Hematology. Blood 1999;94:864-74. [DOI: 10.1182/blood.v94.3.864.415k34_864_874] [Cited by in Crossref: 66] [Article Influence: 3.0] [Reference Citation Analysis]
27 Flotte TR. Recombinant Adeno-Associated Virus Gene Therapy for Cystic Fibrosis and α1-Antitrypsin Deficiency. Chest 2002;121:98S-102S. [DOI: 10.1378/chest.121.3_suppl.98s] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
28 Mah C, Fraites TJ, Zolotukhin I, Song S, Flotte TR, Dobson J, Batich C, Byrne BJ. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther. 2002;6:106-112. [PMID: 12095310 DOI: 10.1006/mthe.2001.0636] [Cited by in Crossref: 131] [Cited by in F6Publishing: 106] [Article Influence: 7.3] [Reference Citation Analysis]
29 Hazari YM, Bashir A, Habib M, Bashir S, Habib H, Qasim MA, Shah NN, Haq E, Teckman J, Fazili KM. Alpha-1-antitrypsin deficiency: Genetic variations, clinical manifestations and therapeutic interventions. Mutat Res. 2017;773:14-25. [PMID: 28927525 DOI: 10.1016/j.mrrev.2017.03.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
30 Flotte TR, Conlon TJ, Poirier A, Campbell-Thompson M, Byrne BJ. Preclinical characterization of a recombinant adeno-associated virus type 1-pseudotyped vector demonstrates dose-dependent injection site inflammation and dissemination of vector genomes to distant sites. Hum Gene Ther 2007;18:245-56. [PMID: 17376008 DOI: 10.1089/hum.2006.113] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
31 Gernoux G, Gruntman AM, Blackwood M, Zieger M, Flotte TR, Mueller C. Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans. Mol Ther 2020;28:747-57. [PMID: 31982038 DOI: 10.1016/j.ymthe.2020.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
32 Chulay JD, Ye GJ, Thomas DL, Knop DR, Benson JM, Hutt JA, Wang G, Humphries M, Flotte TR. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum Gene Ther 2011;22:155-65. [PMID: 20812844 DOI: 10.1089/hum.2010.118] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
33 Lewis AD, Chen R, Montefiori DC, Johnson PR, Clark KR. Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer. J Virol 2002;76:8769-75. [PMID: 12163597 DOI: 10.1128/jvi.76.17.8769-8775.2002] [Cited by in Crossref: 84] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]
34 Gubrij IB, Martin SR, Pangle AK, Kurten R, Johnson LG. Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. Hum Gene Ther 2014;25:498-505. [PMID: 24512101 DOI: 10.1089/hum.2013.187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
35 Duan D, Yue Y, Engelhardt JF. Consequences of DNA-dependent protein kinase catalytic subunit deficiency on recombinant adeno-associated virus genome circularization and heterodimerization in muscle tissue. J Virol 2003;77:4751-9. [PMID: 12663782 DOI: 10.1128/jvi.77.8.4751-4759.2003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
36 Raisler BJ, Berns KI, Grant MB, Beliaev D, Hauswirth WW. Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci U S A 2002;99:8909-14. [PMID: 12072560 DOI: 10.1073/pnas.122247299] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
37 Breous E, Somanathan S, Wilson JM. BALB/c mice show impaired hepatic tolerogenic response following AAV gene transfer to the liver. Mol Ther 2010;18:766-74. [PMID: 20068550 DOI: 10.1038/mt.2009.301] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
38 Snyder RO. Adeno-associated virus-mediated gene delivery. J Gene Med 1999;1:166-75. [DOI: 10.1002/(sici)1521-2254(199905/06)1:3<166::aid-jgm34>3.0.co;2-z] [Cited by in Crossref: 73] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
39 Flotte TR. Adeno-Associated Virus-Mediated Gene Transfer for Lung Diseases. Human Gene Therapy 2005;16:643-8. [DOI: 10.1089/hum.2005.16.643] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
40 Watanabe M, Nasu Y, Kashiwakura Y, Kusumi N, Tamayose K, Nagai A, Sasano T, Shimada T, Daida H, Kumon H. Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth. Hum Gene Ther. 2005;16:699-710. [PMID: 15960601 DOI: 10.1089/hum.2005.16.699] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
41 Padron E, Bowman V, Kaludov N, Govindasamy L, Levy H, Nick P, McKenna R, Muzyczka N, Chiorini JA, Baker TS, Agbandje-McKenna M. Structure of adeno-associated virus type 4. J Virol 2005;79:5047-58. [PMID: 15795290 DOI: 10.1128/JVI.79.8.5047-5058.2005] [Cited by in Crossref: 71] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
42 Peng HH, Wu S, Davis JJ, Wang L, Roth JA, Marini FC 3rd, Fang B. A rapid and efficient method for purification of recombinant adenovirus with arginine-glycine-aspartic acid-modified fibers. Anal Biochem 2006;354:140-7. [PMID: 16707084 DOI: 10.1016/j.ab.2006.04.032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
43 Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, Hutnick NA, Betts MR, Kastelein JJ, Stroes ES. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood. 2009;114:2077-2086. [PMID: 19506302 DOI: 10.1182/blood-2008-07-167510] [Cited by in Crossref: 177] [Cited by in F6Publishing: 162] [Article Influence: 14.8] [Reference Citation Analysis]
44 Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, Rouhani F, Conlon TJ, Calcedo R, Betts MR. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A. 2009;106:16363-16368. [PMID: 19706466 DOI: 10.1073/pnas.0904514106] [Cited by in Crossref: 218] [Cited by in F6Publishing: 199] [Article Influence: 18.2] [Reference Citation Analysis]
45 Thomas PB, Samant DM, Selvam S, Wei RH, Wang Y, Stevenson D, Schechter JE, Apparailly F, Mircheff AK, Trousdale MD. Adeno-associated virus-mediated IL-10 gene transfer suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Invest Ophthalmol Vis Sci 2010;51:5137-44. [PMID: 20505195 DOI: 10.1167/iovs.10-5423] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
46 Chen S, Agarwal A, Glushakova OY, Jorgensen MS, Salgar SK, Poirier A, Flotte TR, Croker BP, Madsen KM, Atkinson MA, Hauswirth WW, Berns KI, Tisher CC. Gene Delivery in Renal Tubular Epithelial Cells Using Recombinant Adeno-Associated Viral Vectors. JASN 2003;14:947-58. [DOI: 10.1097/01.asn.0000057858.45649.f7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
47 Song S, Lu Y, Choi YK, Han Y, Tang Q, Zhao G, Berns KI, Flotte TR. DNA-dependent PK inhibits adeno-associated virus DNA integration. Proc Natl Acad Sci U S A 2004;101:2112-6. [PMID: 14766968 DOI: 10.1073/pnas.0307833100] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 4.4] [Reference Citation Analysis]
48 Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, Campbell-Thompson M, Yachnis AT, Sandhaus RA, McElvaney NG, Mueller C, Messina LM, Wilson JM, Brantly M, Knop DR, Ye GJ, Chulay JD. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum Gene Ther 2011;22:1239-47. [PMID: 21609134 DOI: 10.1089/hum.2011.053] [Cited by in Crossref: 217] [Cited by in F6Publishing: 175] [Article Influence: 21.7] [Reference Citation Analysis]
49 Song S, Laipis PJ, Berns KI, Flotte TR. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci U S A 2001;98:4084-8. [PMID: 11274433 DOI: 10.1073/pnas.061014598] [Cited by in Crossref: 91] [Cited by in F6Publishing: 74] [Article Influence: 4.6] [Reference Citation Analysis]
50 Hauck B, Chen L, Xiao W. Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 2003;7:419-25. [PMID: 12668138 DOI: 10.1016/s1525-0016(03)00012-1] [Cited by in Crossref: 104] [Cited by in F6Publishing: 45] [Article Influence: 5.8] [Reference Citation Analysis]
51 Sondhi D, Stiles KM, De BP, Crystal RG. Genetic Modification of the Lung Directed Toward Treatment of Human Disease. Hum Gene Ther 2017;28:3-84. [PMID: 27927014 DOI: 10.1089/hum.2016.152] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
52 Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, High KA. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012;119:3038-41. [PMID: 22271447 DOI: 10.1182/blood-2011-09-382317] [Cited by in Crossref: 126] [Cited by in F6Publishing: 116] [Article Influence: 14.0] [Reference Citation Analysis]
53 Patel DH, Misra A. Gene Delivery Using Viral Vectors. Challenges in Delivery of Therapeutic Genomics and Proteomics. Elsevier; 2011. pp. 207-70. [DOI: 10.1016/b978-0-12-384964-9.00005-0] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
54 Raisler BJ, Deng W, I. Berns K, Hauswirth WW. Adeno‐associated virus mediated gene therapy for vascular retinopathies. Adeno-Associated Viral Vectors for Gene Therapy. Elsevier; 2005. pp. 103-23. [DOI: 10.1016/s0075-7535(05)31005-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Loring HS, Flotte TR. Current status of gene therapy for α-1 antitrypsin deficiency. Expert Opinion on Biological Therapy 2015;15:329-36. [DOI: 10.1517/14712598.2015.978854] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
56 Chen B, Kapturczak MH, Joseph R, George JF, Campbell-Thompson M, Wasserfall CH, Atkinson MA, Tisher CC, Flotte TR, Agarwal A. Adeno-associated viral vector-mediated interleukin-10 prolongs allograft survival in a rat kidney transplantation model. Am J Transplant. 2007;7:1112-1120. [PMID: 17456199 DOI: 10.1111/j.1600-6143.2007.01772.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
57 Tahara I, Miyake K, Hanawa H, Kurai T, Hirai Y, Ishizaki M, Uchida E, Tajiri T, Shimada T. Systemic cancer gene therapy using adeno-associated virus type 1 vector expressing MDA-7/IL24. Mol Ther 2007;15:1805-11. [PMID: 17551500 DOI: 10.1038/sj.mt.6300225] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
58 Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A 1999;96:3906-10. [PMID: 10097136 DOI: 10.1073/pnas.96.7.3906] [Cited by in Crossref: 167] [Cited by in F6Publishing: 150] [Article Influence: 7.6] [Reference Citation Analysis]
59 Fischer AC, Smith CI, Cebotaru L, Zhang X, Askin FB, Wright J, Guggino SE, Adams RJ, Flotte T, Guggino WB. Expression of a Truncated Cystic Fibrosis Transmembrane Conductance Regulator with an AAV5-pseudotyped Vector in Primates. Molecular Therapy 2007;15:756-63. [DOI: 10.1038/sj.mt.6300059] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
60 Goudy K, Song S, Wasserfall C, Zhang YC, Kapturczak M, Muir A, Powers M, Scott-Jorgensen M, Campbell-Thompson M, Crawford JM, Ellis TM, Flotte TR, Atkinson MA. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci U S A 2001;98:13913-8. [PMID: 11717448 DOI: 10.1073/pnas.251532298] [Cited by in Crossref: 108] [Cited by in F6Publishing: 90] [Article Influence: 5.7] [Reference Citation Analysis]
61 Chotirmall SH, Al-Alawi M, McEnery T, McElvaney NG. Alpha-1 proteinase inhibitors for the treatment of alpha-1 antitrypsin deficiency: safety, tolerability, and patient outcomes. Ther Clin Risk Manag 2015;11:143-51. [PMID: 25673994 DOI: 10.2147/TCRM.S51474] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
62 Kolb M, Martin G, Medina M, Ask K, Gauldie J. Gene therapy for pulmonary diseases. Chest 2006;130:879-84. [PMID: 16963689 DOI: 10.1378/chest.130.3.879] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
63 Logan GJ, Wang L, Zheng M, Cunningham SC, Coppel RL, Alexander IE. AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. Vaccine 2007;25:1014-22. [DOI: 10.1016/j.vaccine.2006.09.072] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
64 Wilson AA, Murphy GJ, Hamakawa H, Kwok LW, Srinivasan S, Hovav AH, Mulligan RC, Amar S, Suki B, Kotton DN. Amelioration of emphysema in mice through lentiviral transduction of long-lived pulmonary alveolar macrophages. J Clin Invest. 2010;120:379-389. [PMID: 20038801 DOI: 10.1172/JCI36666] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
65 Sosulski ML, Stiles KM, Frenk EZ, Hart FM, Matsumura Y, De BP, Kaminsky SM, Crystal RG. Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin. JCI Insight 2020;5:135951. [PMID: 32759494 DOI: 10.1172/jci.insight.135951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Zhang D, Wu M, Nelson DE, Pasula R, Martin WJ 2nd. Alpha-1-antitrypsin expression in the lung is increased by airway delivery of gene-transfected macrophages. Gene Ther 2003;10:2148-52. [PMID: 14625570 DOI: 10.1038/sj.gt.3302121] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
67 Tonelli AR, Brantly ML. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. Ther Adv Respir Dis 2010;4:289-312. [DOI: 10.1177/1753465810373911] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
68 Brantly ML, Spencer LT, Humphries M, Conlon TJ, Spencer CT, Poirier A, Garlington W, Baker D, Song S, Berns KI, Muzyczka N, Snyder RO, Byrne BJ, Flotte TR. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006;17:1177-86. [PMID: 17115945 DOI: 10.1089/hum.2006.17.1177] [Cited by in Crossref: 124] [Cited by in F6Publishing: 113] [Article Influence: 8.9] [Reference Citation Analysis]
69 Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004;10:302-17. [PMID: 15294177 DOI: 10.1016/j.ymthe.2004.05.024] [Cited by in Crossref: 515] [Cited by in F6Publishing: 467] [Article Influence: 32.2] [Reference Citation Analysis]
70 Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103:2136-2141; quiz 2142. [PMID: 18796107 DOI: 10.1111/j.1572-0241.2008.01955.x] [Cited by in Crossref: 152] [Cited by in F6Publishing: 91] [Article Influence: 11.7] [Reference Citation Analysis]
71 Chiuchiolo MJ, Crystal RG. Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease. Ann Am Thorac Soc 2016;13 Suppl 4:S352-69. [PMID: 27564673 DOI: 10.1513/AnnalsATS.201506-344KV] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
72 Hacker U, Gerner F, Büning H, Hutter M, Reichenspurner H, Stangl M, Hallek M. Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors. Gene Ther 2001;8:966-8. [DOI: 10.1038/sj.gt.3301466] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
73 Bañuls L, Pellicer D, Castillo S, Navarro-García MM, Magallón M, González C, Dasí F. Gene Therapy in Rare Respiratory Diseases: What Have We Learned So Far? J Clin Med 2020;9:E2577. [PMID: 32784514 DOI: 10.3390/jcm9082577] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
74 Sandhaus RA. alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency. Thorax 2004;59:904-9. [PMID: 15454659 DOI: 10.1136/thx.2003.006551] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
75 Lewis EC, Shapiro L, Bowers OJ, Dinarello CA. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci USA. 2005;102:12153-12158. [PMID: 16093309 DOI: 10.1073/pnas.0505579102] [Cited by in Crossref: 127] [Cited by in F6Publishing: 120] [Article Influence: 7.9] [Reference Citation Analysis]
76 Goudy KS, Burkhardt BR, Wasserfall C, Song S, Campbell-Thompson ML, Brusko T, Powers MA, Clare-Salzler MJ, Sobel ES, Ellis TM, Flotte TR, Atkinson MA. Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol 2003;171:2270-8. [PMID: 12928371 DOI: 10.4049/jimmunol.171.5.2270] [Cited by in Crossref: 98] [Cited by in F6Publishing: 78] [Article Influence: 5.4] [Reference Citation Analysis]
77 Mulgrew AT, Taggart CC, Mcelvaney NG. Alpha-1-Antitrypsin Deficiency: Current Concepts. Lung 2007;185:191-201. [DOI: 10.1007/s00408-007-9009-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
78 Song S. Alpha-1 Antitrypsin Therapy for Autoimmune Disorders. Chronic Obstr Pulm Dis 2018;5:289-301. [PMID: 30723786 DOI: 10.15326/jcopdf.5.4.2018.0131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
79 Stoll SM, Sclimenti CR, Baba EJ, Meuse L, Kay MA, Calos MP. Epstein-Barr virus/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. Mol Ther 2001;4:122-9. [PMID: 11482983 DOI: 10.1006/mthe.2001.0429] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 3.6] [Reference Citation Analysis]
80 Turner AM. Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies. BioDrugs 2013;27:547-58. [PMID: 23771682 DOI: 10.1007/s40259-013-0042-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
81 Winbanks CE, Beyer C, Qian H, Gregorevic P. Transduction of skeletal muscles with common reporter genes can promote muscle fiber degeneration and inflammation. PLoS One 2012;7:e51627. [PMID: 23251598 DOI: 10.1371/journal.pone.0051627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
82 Chen MJ, Lu Y, Hamazaki T, Tsai HY, Erger K, Conlon T, Elshikha AS, Li H, Srivastava A, Yao C, Brantly M, Chiodo V, Hauswirth W, Terada N, Song S. Reprogramming adipose tissue-derived mesenchymal stem cells into pluripotent stem cells by a mutant adeno-associated viral vector. Hum Gene Ther Methods 2014;25:72-82. [PMID: 24191859 DOI: 10.1089/hgtb.2013.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
83 Flotte TR. Adeno-associated virus-based gene therapy for inherited disorders. Pediatr Res 2005;58:1143-7. [PMID: 16306183 DOI: 10.1203/01.pdr.0000189226.03684.fe] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
84 Aarnisalo AA, Pietola L, Joensuu J, Isosomppi J, Aarnisalo P, Dinculescu A, Lewin AS, Flannery J, Hauswirth WW, Sankila EM. Anti-clarin-1 AAV-delivered ribozyme induced apoptosis in the mouse cochlea. Hear Res. 2007;230:9-16. [PMID: 17493778 DOI: 10.1016/j.heares.2007.03.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
85 Watchko J, O'day T, Wang B, Zhou L, Tang Y, Li J, Xiao X. Adeno-Associated Virus Vector-Mediated Minidystrophin Gene Therapy Improves Dystrophic Muscle Contractile Function in mdx Mice. Human Gene Therapy 2002;13:1451-60. [DOI: 10.1089/10430340260185085] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 5.2] [Reference Citation Analysis]
86 Monahan PE, Jooss K, Sands MS. Safety of adeno-associated virus gene therapy vectors: a current evaluation. Expert Opinion on Drug Safety 2005;1:79-91. [DOI: 10.1517/14740338.1.1.79] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
87 Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J Virol 2000;74:992-6. [PMID: 10623762 DOI: 10.1128/jvi.74.2.992-996.2000] [Cited by in Crossref: 119] [Cited by in F6Publishing: 65] [Article Influence: 5.7] [Reference Citation Analysis]
88 Conway JE, Rhys CM, Zolotukhin I, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 1999;6:986-93. [PMID: 10455400 DOI: 10.1038/sj.gt.3300937] [Cited by in Crossref: 116] [Cited by in F6Publishing: 100] [Article Influence: 5.5] [Reference Citation Analysis]
89 Chen S, Kapturczak M, Loiler SA, Zolotukhin S, Glushakova OY, Madsen KM, Samulski RJ, Hauswirth WW, Campbell-Thompson M, Berns KI, Flotte TR, Atkinson MA, Tisher CC, Agarwal A. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther 2005;16:235-47. [PMID: 15761263 DOI: 10.1089/hum.2005.16.235] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
90 Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A 2000;97:13714-9. [PMID: 11095710 DOI: 10.1073/pnas.240335297] [Cited by in Crossref: 322] [Cited by in F6Publishing: 270] [Article Influence: 16.1] [Reference Citation Analysis]
91 Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon? Gene Ther. 2000;7:24-30. [PMID: 10680012 DOI: 10.1038/sj.gt.3301109] [Cited by in Crossref: 219] [Cited by in F6Publishing: 184] [Article Influence: 10.4] [Reference Citation Analysis]
92 Ferreira V, Petry H, Salmon F. Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside. Front Immunol. 2014;5:82. [PMID: 24624131 DOI: 10.3389/fimmu.2014.00082] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 8.4] [Reference Citation Analysis]
93 Lu Y, Choi Y, Campbell-thompson M, Li C, Tang Q, Crawford JM, Flotte TR, Song S. Therapeutic level of functional human alpha 1 antitrypsin (hAAT) secreted from murine muscle transduced by adeno-associated virus (rAAV1) vector. J Gene Med 2006;8:730-5. [DOI: 10.1002/jgm.896] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
94 Hartung SD, Reddy RG, Whitley CB, Mcivor RS. Enzymatic Correction and Cross-Correction of Mucopolysaccharidosis Type I Fibroblasts by Adeno-Associated Virus-Mediated Transduction of the alpha-L-Iduronidase Gene. Human Gene Therapy 1999;10:2163-72. [DOI: 10.1089/10430349950017158] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
95 Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 2005;105:4226-34. [PMID: 15713796 DOI: 10.1182/blood-2004-03-0848] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 4.4] [Reference Citation Analysis]
96 Cruz PE, Mueller C, Flotte TR. The promise of gene therapy for the treatment of alpha-1 antitrypsin deficiency. Pharmacogenomics 2007;8:1191-8. [PMID: 17924834 DOI: 10.2217/14622416.8.9.1191] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
97 Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther 2005;16:541-50. [PMID: 15916479 DOI: 10.1089/hum.2005.16.541] [Cited by in Crossref: 145] [Cited by in F6Publishing: 124] [Article Influence: 9.1] [Reference Citation Analysis]
98 Stein H, Foss HD, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95. [PMID: 11090048 [PMID: 11090048 DOI: 10.1053/beha.2000.0100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
99 Sun JY, Anand-jawa V, Chatterjee S, Wong KK. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther 2003;10:964-76. [DOI: 10.1038/sj.gt.3302039] [Cited by in Crossref: 157] [Cited by in F6Publishing: 121] [Article Influence: 8.7] [Reference Citation Analysis]
100 McGee Sanftner LH, Rendahl KG, Quiroz D, Coyne M, Ladner M, Manning WC, Flannery JG. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Mol Ther 2001;3:688-96. [PMID: 11356074 DOI: 10.1006/mthe.2001.0308] [Cited by in Crossref: 65] [Cited by in F6Publishing: 57] [Article Influence: 3.3] [Reference Citation Analysis]
101 Baum BJ, Goldsmith CM, Kok MR, Lodde BM, van Mello NM, Voutetakis A, Wang J, Yamano S, Zheng C. Advances in vector-mediated gene transfer. Immunology Letters 2003;90:145-9. [DOI: 10.1016/j.imlet.2003.08.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
102 Aikawa R, Huggins GS, Snyder RO. Cardiomyocyte-specific gene expression following recombinant adeno-associated viral vector transduction. J Biol Chem. 2002;277:18979-18985. [PMID: 11889137 DOI: 10.1074/jbc.m201257200] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
103 Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for the muscular dystrophies: Successes, limitations and recent advances. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2007;1772:243-62. [DOI: 10.1016/j.bbadis.2006.09.007] [Cited by in Crossref: 75] [Cited by in F6Publishing: 59] [Article Influence: 5.4] [Reference Citation Analysis]
104 Huang X, Yang Y. Innate immune recognition of viruses and viral vectors. Hum Gene Ther 2009;20:293-301. [PMID: 19272012 DOI: 10.1089/hum.2008.141] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 4.8] [Reference Citation Analysis]
105 Yu DL, Stegelmeier AA, Chow N, Rghei AD, Matuszewska K, Lawler J, Bridle BW, Petrik JJ, Wootton SK. AAV-mediated expression of 3TSR inhibits tumor and metastatic lesion development and extends survival in a murine model of epithelial ovarian carcinoma. Cancer Gene Ther 2020;27:356-67. [PMID: 31160686 DOI: 10.1038/s41417-019-0108-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Song S, Goudy K, Campbell-Thompson M, Wasserfall C, Scott-Jorgensen M, Wang J, Tang Q, Crawford JM, Ellis TM, Atkinson MA, Flotte TR. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther 2004;11:181-6. [PMID: 14712302 DOI: 10.1038/sj.gt.3302156] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 4.5] [Reference Citation Analysis]
107 Muhuri M, Zhan W, Maeda Y, Li J, Lotun A, Chen J, Sylvia K, Dasgupta I, Arjomandnejad M, Nixon T, Keeler AM, Manokaran S, He R, Su Q, Tai PWL, Gao G. Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction. Front Immunol 2021;12:674242. [PMID: 33995418 DOI: 10.3389/fimmu.2021.674242] [Reference Citation Analysis]
108 De BP, Heguy A, Hackett NR, Ferris B, Leopold PL, Lee J, Pierre L, Gao G, Wilson JM, Crystal RG. High Levels of Persistent Expression of α1-Antitrypsin Mediated by the Nonhuman Primate Serotype rh.10 Adeno-associated Virus Despite Preexisting Immunity to Common Human Adeno-associated Viruses. Molecular Therapy 2006;13:67-76. [DOI: 10.1016/j.ymthe.2005.09.003] [Cited by in Crossref: 89] [Cited by in F6Publishing: 87] [Article Influence: 5.9] [Reference Citation Analysis]
109 Metz R, DiCola M, Kurihara T, Bailey A, Frank B, Roecklein B, Blaese M. Mode of action of RNA/DNA oligonucleotides: progress in the development of gene repair as a therapy for alpha(1)-antitrypsin deficiency. Chest 2002;121:91S-7S. [PMID: 11893721 DOI: 10.1378/chest.121.3_suppl.91s] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
110 Wood AM, Stockley RA. Alpha one antitrypsin deficiency: from gene to treatment. Respiration 2007;74:481-92. [PMID: 17671403 DOI: 10.1159/000105536] [Cited by in Crossref: 50] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
111 Hauswirth WW, Lewin AS. Ribozyme uses in retinal gene therapy. Prog Retin Eye Res 2000;19:689-710. [PMID: 11029552 DOI: 10.1016/s1350-9462(00)00007-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
112 Moulay G, Masurier C, Bigey P, Scherman D, Kichler A. Soluble TNF-α receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer. Gene Ther 2010;17:1400-10. [PMID: 20596058 DOI: 10.1038/gt.2010.94] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
113 Wang L, Louboutin JP, Bell P, Greig JA, Li Y, Wu D, Wilson JM. Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. J Thromb Haemost 2011;9:2009-19. [PMID: 21883883 DOI: 10.1111/j.1538-7836.2011.04491.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
114 American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818-900. [PMID: 14522813 DOI: 10.1164/rccm.168.7.818] [Cited by in Crossref: 612] [Cited by in F6Publishing: 433] [Article Influence: 43.7] [Reference Citation Analysis]
115 Cheng H, Wolfe SH, Valencia V, Qian K, Shen L, Phillips MI, Chang L, Zhang YC. Efficient and persistent transduction of exocrine and endocrine pancreas by adeno-associated virus type 8. J Biomed Sci 2007;14:585-94. [DOI: 10.1007/s11373-007-9159-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
116 Stolk J, Seersholm N, Kalsheker N. Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management. Int J Chron Obstruct Pulmon Dis 2006;1:151-60. [PMID: 18046892 DOI: 10.2147/copd.2006.1.2.151] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
117 Zhang Y, Powers M, Wasserfall C, Brusko T, Song S, Flotte T, Snyder R, Potter M, Scott-jorgensen M, Campbell-thompson M, Crawford J, Nick H, Agarwal A, Ellis T, Atkinson M. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity. Gene Ther 2004;11:233-40. [DOI: 10.1038/sj.gt.3302144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
118 Büeler H. Adeno-associated viral vectors for gene transfer and gene therapy. Biol Chem 1999;380:613-22. [PMID: 10430026 DOI: 10.1515/BC.1999.078] [Cited by in Crossref: 61] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
119 Paz H, Wong CA, Li W, Santat L, Wong KK, Chatterjee S. Quiescent subpopulations of human CD34-positive hematopoietic stem cells are preferred targets for stable recombinant adeno-associated virus type 2 transduction. Hum Gene Ther 2007;18:614-26. [PMID: 17638572 DOI: 10.1089/hum.2006.188] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
120 Irby RB, Kline CL. Par-4 as a potential target for cancer therapy. Expert Opin Ther Targets 2013;17:77-87. [PMID: 23062118 DOI: 10.1517/14728222.2013.731047] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
121 Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ, Sands MS, Parker Ponder K. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001;12:563-73. [PMID: 11268288 DOI: 10.1089/104303401300042500] [Cited by in Crossref: 129] [Cited by in F6Publishing: 118] [Article Influence: 6.5] [Reference Citation Analysis]
122 Valdmanis PN, Kay MA. Future of rAAV Gene Therapy: Platform for RNAi, Gene Editing, and Beyond. Hum Gene Ther 2017;28:361-72. [PMID: 28073291 DOI: 10.1089/hum.2016.171] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 8.5] [Reference Citation Analysis]
123 Lu Y, Parker M, Pileggi A, Zhang B, Choi YK, Molano RD, Wasserfall C, Ricordi C, Inverardi L, Brantly M, Schatz D, Atkinson M, Song S. Human alpha 1-antitrypsin therapy induces fatal anaphylaxis in non-obese diabetic mice. Clin Exp Immunol 2008;154:15-21. [PMID: 18759852 DOI: 10.1111/j.1365-2249.2008.03721.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
124 Owen R, Mandel RJ, Ammini CV, Conlon TJ, Kerr DS, Stacpoole PW, Flotte TR. Gene Therapy for Pyruvate Dehydrogenase E1α Deficiency Using Recombinant Adeno-Associated Virus 2 (rAAV2) Vectors. Molecular Therapy 2002;6:394-9. [DOI: 10.1006/mthe.2002.0683] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
125 Flotte TR, Mueller C. Gene therapy for alpha-1 antitrypsin deficiency. Hum Mol Genet 2011;20:R87-92. [PMID: 21498872 DOI: 10.1093/hmg/ddr156] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
126 Watanabe M, Kashiwakura Y, Kusumi N, Tamayose K, Nasu Y, Nagai A, Shimada T, Daida H, Kumon H. Adeno-associated virus-mediated human IL-10 gene transfer suppresses the development of experimental autoimmune orchitis. Gene Ther 2005;12:1126-32. [PMID: 15920464 DOI: 10.1038/sj.gt.3302463] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
127 Moreno AM, Palmer N, Alemán F, Chen G, Pla A, Jiang N, Leong Chew W, Law M, Mali P. Immune-orthogonal orthologues of AAV capsids and of Cas9 circumvent the immune response to the administration of gene therapy. Nat Biomed Eng 2019;3:806-16. [PMID: 31332341 DOI: 10.1038/s41551-019-0431-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
128 Byrne PI, Collins S, Mah CC, Smith B, Conlon T, Martin SD, Corti M, Cleaver B, Islam S, Lawson LA. Phase I/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease. Hum Gene Ther Clin Dev 2014;25:134-63. [PMID: 25238277 DOI: 10.1089/humc.2014.2514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
129 Favre D, Provost N, Blouin V, Blancho G, Chérel Y, Salvetti A, Moullier P. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol Ther 2001;4:559-66. [PMID: 11735340 DOI: 10.1006/mthe.2001.0494] [Cited by in Crossref: 88] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
130 Driskell RA, Engelhardt JF. Current status of gene therapy for inherited lung diseases. Annu Rev Physiol 2003;65:585-612. [PMID: 12524461 DOI: 10.1146/annurev.physiol.65.092101.142426] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
131 Song S, Embury J, Laipis PJ, Berns KI, Crawford JM, Flotte TR. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2001;8:1299-306. [PMID: 11571566 DOI: 10.1038/sj.gt.3301422] [Cited by in Crossref: 120] [Cited by in F6Publishing: 109] [Article Influence: 6.0] [Reference Citation Analysis]
132 Song S, Scott-Jorgensen M, Wang J, Poirier A, Crawford J, Campbell-Thompson M, Flotte TR. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. Mol Ther 2002;6:329-35. [PMID: 12231168 DOI: 10.1006/mthe.2002.0673] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
133 Tal J. Adeno-associated virus-based vectors in gene therapy. J Biomed Sci 2000;7:279-91. [DOI: 10.1007/bf02253246] [Cited by in Crossref: 36] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
134 Song CQ, Wang D, Jiang T, O'Connor K, Tang Q, Cai L, Li X, Weng Z, Yin H, Gao G, Mueller C, Flotte TR, Xue W. In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency. Hum Gene Ther 2018;29:853-60. [PMID: 29597895 DOI: 10.1089/hum.2017.225] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
135 Choi YK, Nash K, Byrne BJ, Muzyczka N, Song S. The effect of DNA-dependent protein kinase on adeno-associated virus replication. PLoS One 2010;5:e15073. [PMID: 21188139 DOI: 10.1371/journal.pone.0015073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
136 Nakai H, Storm TA, Fuess S, Kay MA. Pathways of removal of free DNA vector ends in normal and DNA-PKcs-deficient SCID mouse hepatocytes transduced with rAAV vectors. Hum Gene Ther 2003;14:871-81. [PMID: 12828858 DOI: 10.1089/104303403765701169] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
137 Warrington KH Jr, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet 2006;119:571-603. [PMID: 16612615 DOI: 10.1007/s00439-006-0165-6] [Cited by in Crossref: 100] [Cited by in F6Publishing: 90] [Article Influence: 6.7] [Reference Citation Analysis]
138 Buggio M, Towe C, Annan A, Kaliberov S, Lu ZH, Stephens C, Arbeit JM, Curiel DT. Pulmonary vasculature directed adenovirus increases epithelial lining fluid alpha-1 antitrypsin levels. J Gene Med 2016;18:38-44. [PMID: 26825735 DOI: 10.1002/jgm.2874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
139 Zhang YC, Pileggi A, Molano RD, Wasserfall C, Campbell-thompson M, Ricordi C, Atkinson MA, Inverardi L. Systemic Overexpression of Interleukin-10 Fails to Protect Allogeneic Islet Transplants in Nonobese Diabetic Mice: . Transplantation 2005;80:530-3. [DOI: 10.1097/01.tp.0000168212.53172.06] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
140 Odom GL, Banks GB, Schultz BR, Gregorevic P, Chamberlain JS. Preclinical Studies for Gene Therapy of Duchenne Muscular Dystrophy. J Child Neurol 2010;25:1149-57. [DOI: 10.1177/0883073810371006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
141 Zhang J, Ahn J, Suh Y, Hwang S, Davis ME, Lee K. Identification of CTLA2A, DEFB29, WFDC15B, SERPINA1F and MUP19 as Novel Tissue-Specific Secretory Factors in Mouse. PLoS One 2015;10:e0124962. [PMID: 25946105 DOI: 10.1371/journal.pone.0124962] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
142 Kapturczak M, Zolotukhin S, Cross J, Pileggi A, Molano RD, Jorgensen M, Byrne B, Flotte TR, Ellis T, Inverardi L, Ricordi C, Nick H, Atkinson M, Agarwal A. Transduction of Human and Mouse Pancreatic Islet Cells Using a Bicistronic Recombinant Adeno-associated Viral Vector. Molecular Therapy 2002;5:154-60. [DOI: 10.1006/mthe.2002.0522] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
143 Coakley RJ, Taggart C, O’neill S, Mcelvaney NG. α1-Antitrypsin Deficiency: Biological Answers to Clinical Questions. The American Journal of the Medical Sciences 2001;321:33-41. [DOI: 10.1097/00000441-200101000-00006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
144 Schnepp BC, Chulay JD, Ye GJ, Flotte TR, Trapnell BC, Johnson PR. Recombinant Adeno-Associated Virus Vector Genomes Take the Form of Long-Lived, Transcriptionally Competent Episomes in Human Muscle. Hum Gene Ther 2016;27:32-42. [PMID: 26650966 DOI: 10.1089/hum.2015.136] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
145 Ross CJ, Twisk J, Bakker AC, Miao F, Verbart D, Rip J, Godbey T, Dijkhuizen P, Hermens WT, Kastelein JJ. Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation. Hum Gene Ther. 2006;17:487-499. [PMID: 16716106 DOI: 10.1089/hum.2006.17.487] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
146 Gruntman AM, Flotte TR. Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency. Hum Gene Ther Methods 2015;26:77-81. [PMID: 26067712 DOI: 10.1089/hgtb.2015.086] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
147 Li H, Zhang B, Lu Y, Jorgensen M, Petersen B, Song S. Adipose tissue-derived mesenchymal stem cell-based liver gene delivery. J Hepatol 2011;54:930-8. [PMID: 21168381 DOI: 10.1016/j.jhep.2010.07.051] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
148 Ye GJ, Oshins RA, Rouhani FN, Brantly ML, Chulay JD. Development, validation and use of ELISA for antibodies to human alpha-1 antitrypsin. J Immunol Methods 2013;388:18-24. [PMID: 23195820 DOI: 10.1016/j.jim.2012.11.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
149 Takahashi H, Hirai Y, Migita M, Seino Y, Fukuda Y, Sakuraba H, Kase R, Kobayashi T, Hashimoto Y, Shimada T. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci U S A 2002;99:13777-82. [PMID: 12370426 DOI: 10.1073/pnas.222221899] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
150 Yang M, Ma Q, Dang G, Ma K, Chen P, Zhou C. Adeno-associated virus-mediated bone morphogenetic protein-7 gene transfer induces C2C12 cell differentiation into osteoblast lineage cells1. Acta Pharmacologica Sinica 2005;26:963-8. [DOI: 10.1111/j.1745-7254.2005.00159.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
151 Rivera VM, Ye X, Courage NL, Sachar J, Cerasoli F Jr, Wilson JM, Gilman M. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc Natl Acad Sci U S A 1999;96:8657-62. [PMID: 10411931 DOI: 10.1073/pnas.96.15.8657] [Cited by in Crossref: 129] [Cited by in F6Publishing: 103] [Article Influence: 5.9] [Reference Citation Analysis]
152 Snyder RO, Flotte TR. Production of clinical-grade recombinant adeno-associated virus vectors. Curr Opin Biotechnol 2002;13:418-23. [PMID: 12459331 DOI: 10.1016/s0958-1669(02)00369-5] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
153 Alexander IE, Cunningham SC, Logan GJ, Christodoulou J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther. 2008;15:831-839. [PMID: 18401432 DOI: 10.1038/gt.2008.64] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
154 Conlon TJ, Flotte TR. Recombinant adeno-associated virus vectors for gene therapy. Expert Opinion on Biological Therapy 2005;4:1093-101. [DOI: 10.1517/14712598.4.7.1093] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
155 Chen J, Wu Q, Yang P, Hsu HC, Mountz JD. Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy. Mol Ther 2006;13:260-9. [PMID: 16324888 DOI: 10.1016/j.ymthe.2005.10.006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
156 Lomas DA, Perlmutter DH. Alpha-1-Antitrypsin Deficiency. In: Ramirez-alvarado M, Kelly JW, Dobson CM, editors. Protein Misfolding Diseases. Hoboken: John Wiley & Sons, Inc.; 2010. pp. 403-23. [DOI: 10.1002/9780470572702.ch18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
157 Demers GW, Sugarman BJ, Beltran JC, Westreich LN, Ahmed CM, Lau JY, Hong Z, Lanford RE, Maneval DC. Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles. Toxicol Appl Pharmacol 2002;180:36-42. [PMID: 11922775 DOI: 10.1006/taap.2002.9372] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
158 Shen S, Sanchez ME, Blomenkamp K, Corcoran EM, Marco E, Yudkoff CJ, Jiang H, Teckman JH, Bumcrot D, Albright CF. Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice. Hum Gene Ther 2018;29:861-73. [PMID: 29641323 DOI: 10.1089/hum.2017.227] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
159 Cruz PE, Mueller C, Cossette TL, Golant A, Tang Q, Beattie SG, Brantly M, Campbell-thompson M, Blomenkamp KS, Teckman JH, Flotte TR. In vivo post-transcriptional gene silencing of α-1 antitrypsin by adeno-associated virus vectors expressing siRNA. Lab Invest 2007;87:893-902. [DOI: 10.1038/labinvest.3700629] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
160 Wozniak J, Wandtke T, Kopinski P, Chorostowska-Wynimko J. Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy. Hum Gene Ther 2015;26:709-18. [PMID: 26413996 DOI: 10.1089/hum.2015.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
161 Hauswirth WW, LaVail MM, Flannery JG, Lewin AS. Ribozyme gene therapy for autosomal dominant retinal disease. Clin Chem Lab Med 2000;38:147-53. [PMID: 10834402 DOI: 10.1515/CCLM.2000.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
162 Kriegel C, Attarwala H, Amiji M. Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv Drug Deliv Rev. 2013;65:891-901. [PMID: 23220324 DOI: 10.1016/j.addr.2012.11.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 6.6] [Reference Citation Analysis]
163 Beck SE, Jones LA, Chesnut K, Walsh SM, Reynolds TC, Carter BJ, Askin FB, Flotte TR, Guggino WB. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol 1999;73:9446-55. [PMID: 10516053 DOI: 10.1128/JVI.73.11.9446-9455.1999] [Cited by in Crossref: 76] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
164 Greene CM, Miller SDW, Carroll T, Mclean C, O’mahony M, Lawless MW, O’neill SJ, Taggart CC, Mcelvaney NG. Alpha-1 antitrypsin deficiency: A conformational disease associated with lung and liver manifestations. J Inherit Metab Dis 2008;31:21-34. [DOI: 10.1007/s10545-007-0748-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
165 Walther W, Stein U. Viral Vectors for Gene Transfer: A Review of Their Use in the Treatment of Human Diseases. Drugs 2000;60:249-71. [DOI: 10.2165/00003495-200060020-00002] [Cited by in Crossref: 266] [Cited by in F6Publishing: 198] [Article Influence: 12.7] [Reference Citation Analysis]
166 Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U. Progress and prospects: gene therapy clinical trials (part 1). Gene Ther. 2007;14:1439-1447. [PMID: 17909539 DOI: 10.1038/sj.gt.3303001] [Cited by in Crossref: 80] [Cited by in F6Publishing: 55] [Article Influence: 5.7] [Reference Citation Analysis]
167 Mueller C, Braag SA, Martino AT, Tang Q, Campbell-Thompson M, Flotte TR. The pros and cons of immunomodulatory IL-10 gene therapy with recombinant AAV in a Cftr-/- -dependent allergy mouse model. Gene Ther 2009;16:172-83. [PMID: 18818669 DOI: 10.1038/gt.2008.156] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
168 Flotte TR, Brantly ML, Spencer LT, Byrne BJ, Spencer CT, Baker DJ, Humphries M. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2004;15:93-128. [PMID: 14965381 DOI: 10.1089/10430340460732490] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 3.7] [Reference Citation Analysis]
169 Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000;74:8635-47. [PMID: 10954565 DOI: 10.1128/jvi.74.18.8635-8647.2000] [Cited by in Crossref: 278] [Cited by in F6Publishing: 138] [Article Influence: 13.2] [Reference Citation Analysis]
170 De B, Heguy A, Leopold PL, Wasif N, Korst RJ, Hackett NR, Crystal RG. Intrapleural administration of a serotype 5 adeno-associated virus coding for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin. Molecular Therapy 2004;10:1003-10. [DOI: 10.1016/j.ymthe.2004.08.022] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
171 Loiler SA, Tang Q, Clarke T, Campbell-thompson ML, Chiodo V, Hauswirth W, Cruz P, Perret-gentil M, Atkinson MA, Ramiya VK, Flotte TR. Localized Gene Expression Following Administration of Adeno-associated Viral Vectors via Pancreatic Ducts. Molecular Therapy 2005;12:519-27. [DOI: 10.1016/j.ymthe.2005.04.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
172 Han G, Li Y, Wang J, Wang R, Chen G, Song L, Xu R, Yu M, Wu X, Qian J, Shen B. Active Tolerance Induction and Prevention of Autoimmune Diabetes by Immunogene Therapy Using Recombinant Adenoassociated Virus Expressing Glutamic Acid Decarboxylase 65 Peptide GAD 500–585. J Immunol 2005;174:4516-24. [DOI: 10.4049/jimmunol.174.8.4516] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
173 Mueller C, Gernoux G, Gruntman AM, Borel F, Reeves EP, Calcedo R, Rouhani FN, Yachnis A, Humphries M, Campbell-Thompson M, Messina L, Chulay JD, Trapnell B, Wilson JM, McElvaney NG, Flotte TR. 5 Year Expression and Neutrophil Defect Repair after Gene Therapy in Alpha-1 Antitrypsin Deficiency. Mol Ther 2017;25:1387-94. [PMID: 28408179 DOI: 10.1016/j.ymthe.2017.03.029] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 13.0] [Reference Citation Analysis]
174 Wilson AA, Kwok LW, Hovav AH, Ohle SJ, Little FF, Fine A, Kotton DN. Sustained expression of alpha1-antitrypsin after transplantation of manipulated hematopoietic stem cells. Am J Respir Cell Mol Biol. 2008;39:133-141. [PMID: 18323534 DOI: 10.1165/rcmb.2007-0133OC] [Cited by in Crossref: 46] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
175 Stiles KM, Sondhi D, Kaminsky SM, De BP, Rosenberg JB, Crystal RG. Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease. Chronic Obstr Pulm Dis 2018;5:244-57. [PMID: 30723782 DOI: 10.15326/jcopdf.5.4.2017.0160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
176 Song S, Witek RP, Lu Y, Choi YK, Zheng D, Jorgensen M, Li C, Flotte TR, Petersen BE. Ex vivo transduced liver progenitor cells as a platform for gene therapy in mice. Hepatology. 2004;40:918-924. [PMID: 15382177 DOI: 10.1002/hep.1840400422] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
177 Nathwani AC, Davidoff A, Hanawa H, Zhou J, Vanin EF, Nienhuis AW. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001;97:1258-65. [DOI: 10.1182/blood.v97.5.1258] [Cited by in Crossref: 99] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
178 Xiao X, Li J, Tsao YP, Dressman D, Hoffman EP, Watchko JF. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol 2000;74:1436-42. [PMID: 10627554 DOI: 10.1128/jvi.74.3.1436-1442.2000] [Cited by in Crossref: 78] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
179 Ma H, Lu Y, Lowe K, van der Meijden-Erkelens L, Wasserfall C, Atkinson MA, Song S. Regulated hAAT Expression from a Novel rAAV Vector and Its Application in the Prevention of Type 1 Diabetes. J Clin Med 2019;8:E1321. [PMID: 31466263 DOI: 10.3390/jcm8091321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
180 Stockley RA, Turner AM. α-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends in Molecular Medicine 2014;20:105-15. [DOI: 10.1016/j.molmed.2013.11.006] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
181 Pietola L. Effects of p27 Kip1 - and p53- shRNAs on kanamycin damaged mouse cochlea. WJO 2012;2:1. [DOI: 10.5319/wjo.v2.i1.1] [Reference Citation Analysis]
182 Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, Mccleland ML, Hagstrom J, Pasi K, Ertl HC, Herzog RW, High KA. Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX. Molecular Therapy 2000;1:225-35. [DOI: 10.1006/mthe.2000.0032] [Cited by in Crossref: 104] [Cited by in F6Publishing: 99] [Article Influence: 5.0] [Reference Citation Analysis]
183 Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, Clark KR. Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol 2005;79:955-65. [PMID: 15613324 DOI: 10.1128/JVI.79.2.955-965.2005] [Cited by in Crossref: 72] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
184 Keeler AM, Flotte TR. Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? Annu Rev Virol 2019;6:601-21. [PMID: 31283441 DOI: 10.1146/annurev-virology-092818-015530] [Cited by in Crossref: 76] [Cited by in F6Publishing: 49] [Article Influence: 38.0] [Reference Citation Analysis]
185 Morgan RA, Blaese RM. Gene therapy: lessons learnt from the past decade. Interview by Clare Thompson. BMJ 1999;319:1310. [PMID: 10559061 DOI: 10.1136/bmj.319.7220.1310] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
186 Fraites TJ, Schleissing MR, Shanely R, Walter GA, Cloutier DA, Zolotukhin I, Pauly DF, Raben N, Plotz PH, Powers SK, Kessler PD, Byrne BJ. Correction of the Enzymatic and Functional Deficits in a Model of Pompe Disease Using Adeno-associated Virus Vectors. Molecular Therapy 2002;5:571-8. [DOI: 10.1006/mthe.2002.0580] [Cited by in Crossref: 95] [Cited by in F6Publishing: 85] [Article Influence: 5.0] [Reference Citation Analysis]
187 McNab GL, Ahmad A, Mistry D, Stockley RA. Modification of gene expression and increase in alpha1-antitrypsin (alpha1-AT) secretion after homologous recombination in alpha1-AT-deficient monocytes. Hum Gene Ther 2007;18:1171-7. [PMID: 17937578 DOI: 10.1089/hum.2007.073] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
188 Favre D, Cherel Y, Provost N, Blouin V, Ferry N, Moullier P, Salvetti A. Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene transfer in the rat skeletal muscle. Gene Ther 2000;7:1417-20. [DOI: 10.1038/sj.gt.3301256] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
189 Gruntman AM, Flotte TR. Therapeutics: Gene Therapy for Alpha-1 Antitrypsin Deficiency. Methods Mol Biol 2017;1639:267-75. [PMID: 28752467 DOI: 10.1007/978-1-4939-7163-3_27] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
190 Han G, Wang R, Chen G, Wang J, Xu R, Feng J, Yu M, Wu X, Qian J, Shen B, Li Y. Gene delivery GAD500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: Transduction efficiency do not play important roles. Immunology Letters 2008;115:110-6. [DOI: 10.1016/j.imlet.2007.10.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
191 Marzorati S, Pileggi A, Ricordi C. Allogeneic islet transplantation. Expert Opin Biol Ther 2007;7:1627-45. [PMID: 17961088 DOI: 10.1517/14712598.7.11.1627] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
192 Nash K, Chen W, McDonald WF, Zhou X, Muzyczka N. Purification of host cell enzymes involved in adeno-associated virus DNA replication. J Virol 2007;81:5777-87. [PMID: 17360744 DOI: 10.1128/JVI.02651-06] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
193 Kurosaki F, Uchibori R, Mato N, Sehara Y, Saga Y, Urabe M, Mizukami H, Sugiyama Y, Kume A. Optimization of adeno-associated virus vector-mediated gene transfer to the respiratory tract. Gene Ther 2017;24:290-7. [PMID: 28346434 DOI: 10.1038/gt.2017.19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
194 Flotte TR, Conlon TJ, Mueller C. Preclinical study design for rAAV. Methods Mol Biol 2011;807:317-37. [PMID: 22034037 DOI: 10.1007/978-1-61779-370-7_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
195 Wang Z, Zhu T, Qiao C, Zhou L, Wang B, Zhang J, Chen C, Li J, Xiao X. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005;23:321-328. [PMID: 15735640 DOI: 10.1038/nbt1073] [Cited by in Crossref: 460] [Cited by in F6Publishing: 397] [Article Influence: 28.8] [Reference Citation Analysis]
196 Lu Y, Tang M, Wasserfall C, Kou Z, Campbell-Thompson M, Gardemann T, Crawford J, Atkinson M, Song S. Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther 2006;17:625-34. [PMID: 16776571 DOI: 10.1089/hum.2006.17.625] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 3.9] [Reference Citation Analysis]
197 Dawkins PA, Stockley RA. Animal models of chronic obstructive pulmonary disease. Thorax 2001;56:972-7. [PMID: 11713362 DOI: 10.1136/thorax.56.12.972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]